The study covers important players such as Bayer AG, BeiGene , Biocon , Boehringer Ingelheim GmbH, Boston Biomedical , Bristol-Myers Squibb , Celgene etc
Request a sample report @ https://www.htfmarketreport.com/sample-report/1442068-fallopian-tube-cancer-pipeline-review-5
HTF’s latest Pharmaceutical and Healthcare disease pipeline guide Fallopian Tube Cancer – Pipeline Review, H2 2018, provides an overview of the Fallopian Tube Cancer (Oncology) pipeline landscape.
Fallopian tube cancer is also called tubal cancer. It develops in the fallopian tubes, which serve as a connection between the ovaries and the uterus. It occurs very rarely. The common symptoms of fallopian tube cancer may include abnormal vaginal bleeding, especially after menopause, abdominal pain or a feeling of pressure in the abdomen, abnormal vaginal discharge that is white, clear or pinkish and a pelvic mass at the time of diagnosis, which is present in up to two-thirds of patients. Usually, cancer metastasizes from other parts of the body such as the ovaries or endometrium to the fallopian tubes. Fallopian tube cancer treatment depends on age, the desire to have children, type and stage of the tumor. It usually involves surgery followed by chemotherapy.
Report Highlights
HTF’s Pharmaceutical and Healthcare latest pipeline guide Fallopian Tube Cancer – Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Fallopian Tube Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Fallopian Tube Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Fallopian Tube Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 14, 71, 46, 11, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 7 and 1 molecules, respectively.
Fallopian Tube Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from HTF’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=1442068 Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Fallopian Tube Cancer (Oncology). – The pipeline guide reviews pipeline therapeutics for Fallopian Tube Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. – The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. – The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. – The pipeline guide reviews key companies involved in Fallopian Tube Cancer (Oncology) therapeutics and enlists all their major and minor projects. – The pipeline guide evaluates Fallopian Tube Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. – The pipeline guide encapsulates all the dormant and discontinued pipeline projects. – The pipeline guide reviews latest news related to pipeline therapeutics for Fallopian Tube Cancer (Oncology)
Reasons to buy – Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. – Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. – Find and recognize significant and varied types of therapeutics under development for Fallopian Tube Cancer (Oncology). – Classify potential new clients or partners in the target demographic. – Develop tactical initiatives by understanding the focus areas of leading companies. – Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. – Formulate corrective measures for pipeline projects by understanding Fallopian Tube Cancer (Oncology) pipeline depth and focus of Indication therapeutics. – Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. – Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned in the Report
AbbVie Inc Advenchen Laboratories LLC AiVita Biomedical Inc Aldeyra Therapeutics Inc Altor BioScience Corp Amgen Inc Arrien Pharmaceuticals LLC Astellas Pharma Inc Astex Pharmaceuticals Inc AstraZeneca Plc Atara Biotherapeutics Inc Bayer AG BeiGene Ltd Biocon Ltd Boehringer Ingelheim GmbH Boston Biomedical Inc Bristol-Myers Squibb Co Celgene Corp Celldex Therapeutics Inc Celsion Corp Celyad SA Clovis Oncology Inc Corcept Therapeutics Inc Cotinga Pharmaceuticals Inc Daiichi Sankyo Co Ltd Eisai Co Ltd Eli Lilly and Co EpiThany Inc Exelixis Inc F. Hoffmann-La Roche Ltd Fate Therapeutics Inc Forty Seven Inc Gene Techno Science Co Ltd Genmab A/S GlaxoSmithKline Plc Gradalis Inc Immune Design Corp ImmunoGen Inc IMV Inc Innate Pharma SA InSight Biopharmaceuticals Ltd Jiangsu Hengrui Medicine Co Ltd Johnson & Johnson Juno Therapeutics Inc Karyopharm Therapeutics Inc Kazia Therapeutics Ltd MabVax Therapeutics Holdings Inc Mateon Therapeutics Inc MaxCyte Inc MedImmune LLC Merck & Co Inc Merck KGaA Mersana Therapeutics Inc Millennium Pharmaceuticals Inc Morphotek Inc Mycenax Biotech Inc NewLink Genetics Corp Novartis AG NuCana Plc Oasmia Pharmaceutical AB OBI Pharma Inc Omnitura Therapeutics Inc Oncobiologics Inc Oncolix Inc Oncolytics Biotech Inc OncoMed Pharmaceuticals Inc Ono Pharmaceutical Co Ltd Pfizer Inc Pharma Mar SA Plexxikon Inc Prescient Therapeutics Ltd Protheragen Inc PsiOxus Therapeutics Ltd PTC Therapeutics Inc Regeneron Pharmaceuticals Inc Rgenix Inc Rigel Pharmaceuticals Inc Samyang Holdings Corp Sanofi Sanofi Pasteur SA SELLAS Life Sciences Group Inc Sotio AS Sun Pharma Advanced Research Company Ltd Syndax Pharmaceuticals Inc Synermore Biologics Co Ltd TESARO Inc Tyrogenex Inc (Inactive) Vascular Biogenics Ltd Verastem Inc Vyriad Inc Get Customization in the Report, Enquire Now @ https://www.htfmarketreport.com/enquiry-before-buy/1442068-fallopian-tube-cancer-pipeline-review-5
Table of Contents Table of Contents 2 Introduction 6 Fallopian Tube Cancer – Overview 7 Fallopian Tube Cancer – Therapeutics Development 8 Fallopian Tube Cancer – Therapeutics Assessment 25 Fallopian Tube Cancer – Companies Involved in Therapeutics Development 41 Fallopian Tube Cancer – Drug Profiles 85 Fallopian Tube Cancer – Dormant Projects 1070 Fallopian Tube Cancer – Discontinued Products 1074 Fallopian Tube Cancer – Product Development Milestones 1075 Appendix 1086List of Tables Number of Products under Development for Fallopian Tube Cancer, H2 2018 Number of Products under Development by Companies, H2 2018 Number of Products under Development by Universities/Institutes, H2 2018 Products under Development by Companies, H2 2018 ….Continued
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/1442068-fallopian-tube-cancer-pipeline-review-5 Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.
Media ContactCompany Name: HTF Market Intelligence Consulting Private LimitedContact Person: Craig FrancisEmail: Send EmailPhone: 2063171218Address:Unit No. 429, Parsonage Road City: EdisonState: New JerseyCountry: United StatesWebsite: www.htfmarketreport.com/reports/1442068-fallopian-tube-cancer-pipeline-review-5